Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose 8.2% on Tuesday . The stock traded as high as $14.50 and last traded at $14.37, with a volume of 117,036 shares trading hands. The stock had previously closed at $13.28.

SNDX has been the subject of several research reports. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $24.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 17th. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $25.00.

The company has a 50-day moving average price of $11.50 and a 200 day moving average price of $13.03. The firm’s market capitalization is $252.50 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter. On average, equities analysts expect that Syndax Pharmaceuticals Inc. will post ($2.93) EPS for the current year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.